Director, Assay Development, Illumina
BIOGRAPHY
MAR 21, 2024 10am PDT, 12pm CDT, 1pm EDT
Analytical performance of TruSight™ Oncology 500 ctDNA v2
Part 1 of 2: TSO500 ctDNA v2 series
Speakers
-
Maria Jarama Ruiz, B.S., M.S.
Product Manager, Global Product Management, IlluminaBIOGRAPHY -
Biswajit Das, Ph.D.
Senior Principal Scientist, Frederick National Laboratory for Cancer ResearchBIOGRAPHY
Event Date & Time
Date: March 21, 2024
Time: 10am PDT, 12pm CDT, 1pm EDT
Abstract
Next-generation sequencing (NGS) based liquid biopsy is emerging as standard of care in oncology for comprehensive genomic profiling (CGP) of solid tumors. In this presentation we will showcase the analytical performance of TruSight™ Oncology 500 ctDNA version 2 (TSO 500 ctDNA v2, Illumina, San Diego, CA; Research Use Only), an NGS-based assay that utilizes the same gene panel as TSO 500 ctDNA. Its improved workflow reduces cfDNA input requirements, total turn-around time and hands-on time while still delivering all key biomarker data available from the TSO 500 gene panel.
Learning Objectives
- Understand enhancements and features of TSO 500 ctDNA v2
- Comprehensive overview of analytical performance
- Introduce performance data from an early access customer
Webinars will be available for unlimited on-demand viewing after live event.